In recent years there’s been an increasing convergence between the worlds of health tech and biopharma. Decentralized clinical trials are a great example of this trend. But even before the pandemic that led to the rapid scale of decentralized trials, biopharma companies had been experimenting with various technologies in R&D.
The use of machine learning and other forms of AI for drug development is an exciting trend full of possibilities, especially as the technology matures and companies adapt.
AI in drug development is just one of the panel discussions at the MedCity INVEST PhrmaTech virtual conference, scheduled for Tuesday, July 26.
To view the full agenda, click here. Registration is free.
The conference will explore some of the ways health tech and biopharma intersect, from a conversation on digital medicines to virtual clinical trials.
The panel discussion, the state of AI in drug discovery, will kick off the conference. Here’s a description:
Artificial intelligence in healthcare is finally emerging from being overhyped to showing some practical applications. If it succeeds in the realms of drug discovery, that will be a monumental achievement helping both to speed up and lower the cost for drug development. Learn from experts about where we are in leveraging AI effectively for drug discovery.
Moderator: Frank Vinluan, Senior Biopharma Reporter, MedCity News
Speakers:
- Chris Gibson, Co-founder and CEO, Recursion
- Richard Law, Chief Business Officer, Exscientia
- Najat Khan, Chief Data Science Officer, Global Head Strategy and Operations, Janssen Research and Development
- Eric Steager, Venture Partner, Touchdown Ventures
There will also be a startup pitch contest. It will spotlight companies that are developing technologies to address innovative approaches to clinical trial design, patient recruitment, remote patient monitoring, and more, all of which could transform clinical trials.
Among the judges for Pitch Perfect are:
- Cris De Luca, Partner, Digital, Sanofi Ventures
- Jessica Federer, Partner, Boston Millennia Partners
- Joel Krikston, Managing Director Venture Investments & Head of Strategic Innovation Alliances, Merck Global Health Innovation Fund
- Maxim Owen, Venture Partner, Wavemaker Three-Sixty Health
Interested in sponsorship opportunities at this and other conferences by MedCity News? Please contact MedCity News Publisher Ken Montgomery at [email protected].
Featured Photo: Blue Planet Studio, Getty Images
